Abstract
Purpose
This study aimed to analyze characteristics, treatment, long-term outcomes, and prognostic factors for children, adolescents and young adults with rhabdomysosarcoma (RMS).
Methods
This retrospective historical study included 75 patients with RMS treated between 2002 and 2019. Clinical data and follow-up results were collected including all diagnosis, treatment and prognosis information.
Results
Patients median-age-at-diagnosis was 6 years. Embryonal and alveolar histology occurred in 51 (68.0%) and 21 (28.0%) patients, respectively. The tumors most frequently originated from parameningeal site (28.0%). Of 74 evaluable patients for treatment outcome, 60 (81.1%) achieved complete response for first-line treatment, of whom, 34 (56.6%) maintained complete response, 26 (43.3%; 23/26, local relapse) showed relapse. Of 40 patients with treatment failure, 16 and 6 occurred in parameningeal area and retroperitoneum/perineum, respectively. The 5-year progression-free survival (PFS) and overall survival (OS) were 45.0% and 64.5%, respectively. In multivariate analyses, parameningeal site (p = 0.027), no gross total resection (p = 0.047), and no radiation therapy (RT) (p < 0.001) for PFS; and parameningeal site (p < 0.001) and no RT (p = 0.010) for worse OS, were significant. The median PFS and OS from treatment failure date in 40 patients with primary treatment failure were 1.3 and 4.1 years, respectively. Of 26 patients with relapse, interval to relapse < 7 months, retroperitoneum/perineum site, TNM stages III/IIV, and no salvage RT were independently associated with OS.
Conclusion
The importance of adequate local therapy was highlighted in RMS treatment. Treatment failure was largely a local failure. Whether as a component of initial or salvage treatment, RT could improve patients’ survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Archer NM, Amorim RP, Naves R, Hettmer S, Diller LR, Ribeiro KB et al (2016) An increased risk of second malignant neoplasms after rhabdomyosarcoma: population-based evidence for a cancer predisposition syndrome? Pediatr Blood Cancer 63:196–201. https://doi.org/10.1002/pbc.25678
Bisogno G, De Salvo GL, Bergeron C, Gallego Melcon S, Merks JH, Kelsey A et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:1566–1575. https://doi.org/10.1016/S1470-2045(19)30617-5
Borinstein SC, Steppan D, Hayashi M, Loeb DM, Isakoff MS, Binitie O et al (2018) Consensus and controversies regarding the treatment of rhabdomyosarcoma. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26809
Cameron AL, Elze MC, Casanova M, Geoerger B, Gaze MN, Minard-Colin V et al (2021) The impact of radiation therapy in children and adolescents with metastatic rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 111:968–978. https://doi.org/10.1016/j.ijrobp.2021.06.031
Chen C, Dorado Garcia H, Scheer M, Henssen AG (2019) Current and future treatment strategies for rhabdomyosarcoma. Front Oncol 9:1458. https://doi.org/10.3389/fonc.2019.01458
Clement SC, Schoot RA, Slater O, Chisholm JC, Abela C, Balm AJM et al (2016) Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma. Eur J Cancer 54:1–10. https://doi.org/10.1016/j.ejca.2015.10.064
Crist WM, Kun LE (1991) Common solid tumors of childhood. N Engl J Med 324:461–471. https://doi.org/10.1056/NEJM199102143240706
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB et al (2001) Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 19:3091–3102. https://doi.org/10.1200/JCO.2001.19.12.3091
Dantonello TM, Int-Veen C, Schuck A, Seitz G, Leuschner I, Nathrath M et al (2013) Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma. Pediatr Blood Cancer 60:1267–1273. https://doi.org/10.1002/pbc.24488
de Souza LL, Pontes HAR, Santos-Silva AR, Fernandes LA, Batista LAL, Lopes MA et al (2020) Oral radiation-induced sarcomas: systematic review. Head Neck 42:2660–2668. https://doi.org/10.1002/hed.26176
Eaton BR, McDonald MW, Kim S, Marcus RB Jr, Sutter AL, Chen Z et al (2013) Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: implications for patterns of disease recurrence and overall survival. Cancer 119:1578–1585. https://doi.org/10.1002/cncr.27934
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Gupta AA (2021) Reasonable attempt at a randomized trial in relapsed rhabdomyosarcoma. J Clin Oncol 39:2977–2978. https://doi.org/10.1200/JCO.21.01631
La Quaglia MP, Heller G, Ghavimi F, Casper ES, Vlamis V, Hajdu S et al (1994) The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer 73:109–117. https://doi.org/10.1002/1097-0142(19940101)73:1%3c109::aid-cncr2820730120%3e3.0.co;2-s
Lockney NA, Friedman DN, Wexler LH, Sklar CA, Casey DL, Wolden SL (2016) Late toxicities of intensity-modulated radiation therapy for head and neck rhabdomyosarcoma. Pediatr Blood Cancer 63:1608–1614. https://doi.org/10.1002/pbc.26061
Loeb DM, Thornton K, Shokek O (2008) Pediatric soft tissue sarcomas. Surg Clin North Am 88(615–627):vii. https://doi.org/10.1016/j.suc.2008.03.008
Malempati S, Hawkins DS (2012) Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 59:5–10. https://doi.org/10.1002/pbc.24118
Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Rodeberg DA et al (2019) Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. Cancer 125:2602–2609. https://doi.org/10.1002/cncr.32122
Merks JH, De Salvo GL, Bergeron C, Bisogno G, De Paoli A, Ferrari A et al (2014) Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. Ann Oncol 25:231–236. https://doi.org/10.1093/annonc/mdt426
Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH et al (2008) Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26:2384–2389. https://doi.org/10.1200/JCO.2007.14.7207
Pappo AS, Shapiro DN, Crist WM, Maurer HM (1995) Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13:2123–2139. https://doi.org/10.1200/JCO.1995.13.8.2123
Paulino AC, Simon JH, Zhen W, Wen BC (2000) Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 48:1489–1495. https://doi.org/10.1016/s0360-3016(00)00799-9
Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM et al (2011) Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 29:1312–1318. https://doi.org/10.1200/JCO.2010.30.4469
Roy S, Pathy S, Mohanti BK, Chander S, Biswas A (2017) Adherence to treatment, response and patterns of failure in pediatric parameningeal rhabdomyosarcoma: experience from a tertiary cancer care center from India. J Pediatr Hematol Oncol 39:e62–e68. https://doi.org/10.1097/MPH.0000000000000745
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J et al (2019) Rhabdomyosarcoma. Nat Rev Dis Primers 5(1):1. https://doi.org/10.1038/s41572-018-0051-2
Stevens MC (2005) Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 6:77–84. https://doi.org/10.1016/S1470-2045(05)01733-X
Tefft M, Lindberg RD, Gehan EA (1981) Radiation therapy combined with systemic chemotherapy of rhabdomyosarcoma in children: local control in patients enrolled in the Intergroup Rhabdomyosarcoma Study. Natl Cancer Inst Monogr 56:75–81
Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA et al (2016) Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 34:117–122. https://doi.org/10.1200/JCO.2015.63.4048
Wen Y, Huang D, Zhang W, Zhang Y, Hu H, Li J (2020) Radiation therapy is an important factor to improve survival in pediatric patients with head and neck rhabdomyosarcoma by enhancing local control: a historical cohort study from a single center. BMC Pediatr 20:265. https://doi.org/10.1186/s12887-020-02165-y
Wharam MD, Meza J, Anderson J, Breneman JC, Donaldson SS, Fitzgerald TJ et al (2004) Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 22:1902–1908. https://doi.org/10.1200/JCO.2004.08.124
Winter S, Fasola S, Brisse H, Mosseri V, Orbach D (2015) Relapse after localized rhabdomyosarcoma: evaluation of the efficacy of second-line chemotherapy. Pediatr Blood Cancer 62:1935–1941. https://doi.org/10.1002/pbc.25622
Acknowledgements
This work was supported by a research grant (No. 2210200-1) from the National Cancer Center, Republic of Korea.
Funding
This study was funded by National Cancer Center, Republic of Korea.
Author information
Authors and Affiliations
Contributions
MP: designed the study, analyzed the data, and wrote the manuscript. JAL, HYJ, J-YK, JWP, JHK, HGK, SYP, HJP: contributed the data and reviewed the manuscript. EYP: contributed to analysis of the data. BKP: conceived and designed the study, reviewed the manuscript, and approved the final report.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they do not have any conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Park, M., Lee, J.A., Jin, H.Y. et al. Clinical characteristics and long-term outcomes of rhabdomyosarcoma in Korean children, adolescents and young adults: a single-center experience. J Cancer Res Clin Oncol 149, 3109–3119 (2023). https://doi.org/10.1007/s00432-022-04192-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-04192-x